Thrivent Financial for Lutherans Has $43.47 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Thrivent Financial for Lutherans lifted its position in Agilent Technologies, Inc. (NYSE:A) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 292,789 shares of the medical research company’s stock after buying an additional 8,874 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Agilent Technologies were worth $43,473,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in Agilent Technologies by 13.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after buying an additional 1,042,926 shares during the period. Massachusetts Financial Services Co. MA increased its position in Agilent Technologies by 5.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares during the period. Marshall Wace LLP raised its stake in Agilent Technologies by 48.6% during the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after purchasing an additional 313,155 shares during the last quarter. Impax Asset Management Group plc raised its stake in Agilent Technologies by 8.2% during the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock valued at $396,088,000 after purchasing an additional 203,234 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in Agilent Technologies by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock valued at $442,011,000 after purchasing an additional 183,716 shares during the period.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This trade represents a 19.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. The trade was a 7.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,995 shares of company stock valued at $1,739,510 over the last three months.

Agilent Technologies Trading Down 0.1 %

A stock opened at $126.92 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a twelve month low of $112.39 and a twelve month high of $155.35. The company has a market cap of $36.47 billion, a P/E ratio of 26.33, a PEG ratio of 5.59 and a beta of 1.07. The business has a fifty day moving average of $138.50 and a 200-day moving average of $137.92.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the previous year, the company earned $1.43 EPS. Agilent Technologies’s revenue was down 5.6% on a year-over-year basis. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were given a $0.236 dividend. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.74%. Agilent Technologies’s dividend payout ratio is currently 19.50%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on A. Citigroup upped their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. UBS Group increased their price objective on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Barclays lifted their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research report on Tuesday, October 15th. TD Cowen raised their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Bank of America upped their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and a consensus target price of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.